Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable ...

AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer ...

AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a ...

Imfinzi in combination with chemotherapy has been approved in the European Union, EU, for the treatment of adults with ...

The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...

After Meritain rejected the initial immunotherapy drug, Imfinzi, Brian applied for coverage of a second, similar drug, Keytruda. That, too, was denied. The McNamaras appealed the rulings. Denied again ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer indication in the United States. Imfinzi is approved in combination with ...

On 31 March 2025, AstraZeneca’s Imfinzi treatment for bladder cancer was approved in the US. Trials have shown evidence that the drug could lead to a 25% reduction in the risk of death compared ...

AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer indication in the United States. Imfinzi is approved in combination with ...